



9th EBF Young Scientist Symposium

It's the New Dawn

Defining our (Bioanalytical) Future Together

10-12 May 2023 The Radisson Blu - Hasselt - Belgium

Day 1: Thursday 11 May 2023

8:45 9:00 Welcome and introduction to the 9th YSS

Philip Timmerman, EBF

9:00 10:00 Session 1: Can Automation Deliver on Promise?

Session chairs: Lisa Wolter and Amelia Roberts

9:00 9:20 Rosie Penford, GSK

The Evolution of Automation for Ligand Binding Assays

9:20 9:40 Paul Heads, Orion Corporation

Does automating a bioanalytical laboratory have to cost excessive amounts of time and money?

9:40 10:00 Ewa Cendrowicz, ICON plc

Automated PBMC isolations – gain in time, number of cells and quality of samples

10:00 10:30 Coffee break

10:30 11:50 Session 3: New Tech Entering the BA Toolbox

Session chairs: Mariana Carnerio Da Cunha and Francesca Minelli

10:30 10:50 Kyriel M. Pineault, UCB Pharma (not released for publication)

Qualification of a duplex ddPCR assay to support biodistribution and shedding assessment of a Gene Therapy product

10:50 11:10 Jakob Alhede, AstraZeneca (not released for publication)

Challenges in the application of Branched DNA as a bioanalytical tool for the quantification of RNA therapeutics

9:00 10:00 Session 2: Can we do Less and Achieve More?

Session chairs: Lisa Seavers and Liesl Heughebaert

9:00 9:20 Tammy Speelman, Synexa Life Sciences

Correlation of screening and titre results to reduce analysis costs and increase delivery of patient immunogenicity data

9:20 9:40 Leroy Schreuder, ICON plc

Singlicate analysis applied to pharmacokinetic ligand binding assays: an overview of benefits and limitations.

9:40 10:00 Cathy M. Jacobs, U. Saarbrücken (not released for publication)

Development of an LC-HRMS-based approach for adherence monitoring of breast cancer medication in four different matrices

10:00 10:30 Coffee break

10:30 11:30 Session 1 repeat: Can Automation Deliver on Promise?

Session chairs: Lisa Wolter and Amelia Roberts

10:30 10:50 Rosie Penford, GSK

The Evolution of Automation for Ligand Binding Assays

10:50 11:10 Paul Heads, Orion Corporation

Does automating a bioanalytical laboratory have to cost excessive amounts of time and money?

11:10 11:30 Zoe Georgakopoulou, Drug Development Solutions (DDS)
Streamlining Flow cytometry

11:30 11:50 Victoria Wingfield, Drug Development Solutions (DDS)
Controlling the Flow

11:50 12:00 Introduction to the Science Café (by YSS OC member, tbd)

12:00 13:00 Lunch - tables grouped to start Science Café discussions

13:00 15:30 9th Science Cafe (Format: round table): The Right Balance
Ever since the 4th YSS, a “Science Café” is part of the YSS program. Also this year, we want to include a SC in which we focus on a specific aspect of (y)our community responsibility.
After 3 years of struggle with Covid in a changing world, the 9th YSS SC plans to focus on a theme which is an important challenge: finding the right balance, e.g. work-life balance, technology being an opportunity to refocus, regulations being a challenge or a partner. In short, identifying a SWOT to manage pressure and helping the next generation to grow in responsibility and aspirations. A survey was sent as a stepstone for our discussions.

15:30 16:00 Coffee break

16:00 17:40 Session 4: Troubleshooting LCMS
Session chairs: Manca Spendal and Harriet Thomas

16:00 16:20 Katie Webb, Labcorp Drug Development
The unwanted guest in your chromatography separation

16:20 16:40 Isabel Stiltz, Nuvisan
Combined LC-MS/MS method for a highly instable small molecule and its two metabolites – complication and troubleshooting

16:40 17:00 Sophie Roos, Byondis
Challenges in the development of an LC-MS method for quantitation of sMET in human plasma

17:00 17:20 Xavier Nuno Martinez Galanes, NovoNordisk (not released for publication)
Matrix effect of endogenous lipids in LC-MS/MS analysis of insulin analogues - Part 1: The risk and strategies to reduce their impact.

17:20 17:40 Daniel Alejandro Diaz Checa, NovoNordisk (not released for publication)

11:10 11:30 Ewa Cendrowicz, ICON plc
Automated PBMC isolations – gain in time, number of cells and quality of samples

11:30 11:40 Introduction to the Science Café (by YSS OC member, tbd)

earlier to lunch to minimise queueing

11:40 13:00 Lunch - tables grouped to start Science Café discussions

13:00 15:30 9th Science Cafe (Format: round table): The Right Balance
Ever since the 4th YSS, a “Science Café” is part of the YSS program. Also this year, we want to include a SC in which we focus on a specific aspect of (y)our community responsibility.
After 3 years of struggle with Covid in a changing world, the 9th YSS SC plans to focus on a theme which is an important challenge: finding the right balance, e.g. work-life balance, technology being an opportunity to refocus, regulations being a challenge or a partner. In short, identifying a SWOT to manage pressure and helping the next generation to grow in responsibility and aspirations. A survey was sent as a stepstone for our discussions.

15:30 16:00 Coffee break

16:00 17:40 Session 5: Troubleshooting LBA
Session chairs: Eva Hanckmann and Elien van Nuffel

16:00 16:20 Hannah Vernon-Browne, Drug Development Solutions (DDS)
Bridging immunoassay kits in the biomarker field: Two Case Studies

16:20 16:40 Francesca Minelli, Merck KGaA
Soluble target quantification: challenges in method development

16:40 17:00 Fabian Gärtner, Nuvisan
Avoid the Hook Effect in homogenous MSD assays (Don't get hooked on homogenous assays)

17:00 17:20 Sanam Ahmad, GSK
Troubleshooting analyte carryover on the Gyrolab Platform

17:20 17:40 Ian de Bus, Sanquin Diagnostic Services (not released for publication)

Matrix effect of endogenous lipids in LC-MS/MS analysis of insulin analogues -
Part 2: Development of fully automated sample preparation methods for an
improved sensitivity and reduced matrix suppression

Haemostatic biomarkers; how to correctly analyse them in a quantitative manner?

Day 2: Friday 12 May 2023

- 9:00 9:15 Feedback from the Science Café (by YSS OC member, tbd)**
- 9:15 10:10 Session 2 repeat: Can we do Less and Achieve More?**
Session chairs: Lisa Seavers and Liesl Heughebaert
- 9:15 9:35 Tammy Speelman, Synexa Life Sciences
Correlation of screening and titre results to reduce analysis costs and increase delivery of patient immunogenicity data
- 9:35 9:55 Leroy Schreuder, ICON plc
Singlicate analysis applied to pharmacokinetic ligand binding assays: an overview of benefits and limitations.
- 9:55 10:10 Cathy M. Jacobs, U. Saarbrücken (not released for publication)
Development of an LC-HRMS-based approach for adherence monitoring of breast cancer medication in four different matrices
- 10:10 10:40 Poster Pitches - part 1 extend into poster viewing**
- 10:40 11:30 Discussions @ posters during coffee break**
- 11:30 12:30 Session 6: Getting More out of our Toolbox A**
Session chairs: James Beecroft and Dean Hogan
- 11:30 11:50 Lisa Seavers, Labcorp Drug Development
An alternative approach to the classic anti-drug antibody (ADA) titer assay used in a clinical trial
- 11:50 12:10 Syed Raza ul Haq, AstraZeneca (not presented)
Development of Ligand Binding Assay for PK measurement of mouse surrogates of human therapeutic antibodies in mouse plasma and tissues.
- 12:10 12:30 Sabrina Zadic, Swiss BioQuant
How to adapt and ADA method to a vaccine efficacy study
- earlier to lunch to minimise queueing*
- 12:30 13:20 Lunch break**
- 13:20 14:40 Session 8: Being Tolerant...**

- 9:00 9:15 Feedback from the Science Café (by YSS OC member, tbd)**
- 9:15 10:10 Session 3 repeat: New Tech Entering the BA Toolbox**
Session chairs: Mariana Carnerio Da Cunha and Francesca Minelli
- 9:15 9:35 Kyriel M. Pineault, UCB Pharma(not released for publication)
Qualification of a duplex ddPCR assay to support biodistribution and shedding assessment of a Gene Therapy product
- 9:35 9:55 Jakob Alhede, AstraZeneca (not released for publication)
Challenges in the application of Branched DNA as a bioanalytical tool for the quantification of RNA therapeutics
- 9:55 10:10 Zoe Georgakopoulou, Drug Development Solutions (DDS)
Streamlining Flow cytometry
- 10:10 10:30 Victoria Wingfield, Drug Development Solutions (DDS)
Controlling the Flow
- 10:30 11:00 Poster Pitches - part 2 extend into poster viewing**
- 11:00 11:30 Discussions @ posters during coffee break**
- 11:30 12:50 Session 7: Getting More out of our Toolbox B**
Session chairs: Brian Dan and Claire Szuster
- 11:30 11:50 Fiona Flett, Charles River Laboratories
Glycobiology Growth in the Bioanalytical space: The Development of an LC-MS Assay for Quantitation of Glycosaminoglycans
- 11:50 12:10 Marie Reille-Seroussi, Sanofi
Quantification of next generation biotherapeutics: Recent case studies for which LC-MS showed clear advantages over LBA.
- 12:10 12:30 Patrick Schreier, Abbvie (not released for publication)
Determination of soluble RGMa in human Serum and CSF using LC-MS/MS
- 12:30 12:50 Grigori Singovski, F. Hoffmann - La Roche
Reconciliation: the unsuspected challenge for clinical trials
- 12:50 13:40 Lunch break**
session starts later to allow for 1h lunch and bring program back together

Session chairs: Bodrul Noor and Sabrina Zadic

13:20 13:40 Kenzie Granger, Labcorp Drug Development
Evaluation of multiple ADA assay formats for achieving drug tolerance

13:40 14:00 Lisanne Dijk, Sanquin Diagnostic Services
Development of a novel drug-tolerant ADA assay: the acid-dissociation lanthanide-fluorescence immunoassay (ALFIA)

14:00 14:20 Jayshree Maher, AstraZeneca
The technical challenges of developing target tolerant immunogenicity assays

14:20 14:40 Giorgia Rota, Novartis (not released for publication)
The Challenges of developing functional cell-based neutralizing antibody assays

14:40 15:10 Poster Pitches - part 1 (repeat) extend into poster viewing

15:10 15:30 Discussions @ posters during coffee break

15:30 16:30 Session 10: When Using Multiple Assays A

Session chairs: Joury van't Klooster and James Beecroft

15:30 15:50 Aleksandra Seydel, Novartis AG
Transfer of in-licensed BA Assays for Large Molecule: an uphill Climb to Success

15:50 16:10 Nicholas Butler, F-star Therapeutics
A direct assay comparison between the V-PLEX and S-PLEX proinflammatory panel 1 – Does improved sensitivity equal improved assay?

16:10 16:30 Katja Zeiser, Nuvisan (not released for publication)
The somewhat different clinical study: from first thoughts to the final assay setup

16:30 16:45 Closing Remarks and Announcement 2023 YSS Best Poster Winner

16:45 Adjourn

13:40 14:40 Session 9: Optimising New Tools in Support of Patient Comfort

Session chairs: Lorenzo Marincich and Cathy Jacobs

13:40 14:00 Laura Boffel, U Ghent
In-depth evaluation of automated non-contact reflectance-based hematocrit prediction of dried blood spots

14:00 14:20 Liesl Heughebaert, U Ghent
Application of non-contact hematocrit prediction technologies to overcome hematocrit effects on immunosuppressant quantification from DBS

14:20 14:40 Hanna De Baets, U Ghent (not released for publication)
Capillary application of (volumetric) dried blood spot assays for tacrolimus and creatinine determination in stem cell transplant patients: preliminary results.

14:40 15:10 Poster Pitches - part 2 (repeat) extend into poster viewing

15:10 15:30 Discussions @ posters during coffee break

15:30 16:30 Session 11: When Using Multiple Assays B

Session chairs: Juel Maalouli Schaar and Kyriel Pineault

15:30 15:50 Brian Dan, F. Hoffmann - La Roche
Outsourcing of Small molecule LC-MS bioanalytical methods: when the assay has to be adapted

15:50 16:10 Claire Szuster - DDS
Challenges and considerations for an LC-MS method transfer: Case Study

16:10 16:30 panel discussion: method transfer and cross validation

Meeting Organisation:

Eva Hanckmann, Byondis; Liesl Heughebaert, Ghent University; Elien Van Nuffel, Sanofi; Cathy Jacobs, Saarland University; Kate Groves, UCB Pharma (until 15JAN2023), Kyriel Pineault, UCB Pharma (From 16JAN2023); Lisa Wolter, Abbvie; Paul Heads, Orion Corporation; Sabrina Zadic, Swiss Bioquant; Katja Zeiser, Nuvisan; Claire Szuster, DDS; Manca Spendal, NovoNordisk; Amelia Roberts, Quotient Sciences; Harriet Thomas, GSK; Bodrul Noor, AstraZeneca; Mariana Carneiro Da Cunha, Intertek; Joury van 't Klooster, ICON plc ; Marie Reille-Seroussi, Sanofi; Francesca Minelli, Merck KGaA; Brian Dan, F. Hoffmann La Roche; James Beecroft, F. Hoffmann La Roche; Lisa Seavers, Labcorp Drug Development; Juel Maalouli Schaar, Saarland University; Giusy Tespio, Unibo (until 31JAN2023); Lorenzo Marincich, Unibo (From 01FEB2023) and Dean Hogan, Charles River Laboratories.

Meeting Management: Philip Timmerman (EBF)

The symposium is organised as a non-profit event by the EBF vzw. The organisation of the conference is independent of all EBF member companies.